Although increased plasma levels of IgA1 and IgA1-containing immune complexes (IC) occur in several human diseases, their deposition into kidney mesangium is characteristic of IgA nephropathy (IgAN). Recent studies indicate that IgA1 proteins from plasma of IgAN patients are characterized by structurally altered oligosaccharide side chains. Carbohydrate analyses and reactivities with lectins revealed that IgA from IgAN patients is deficiently galactosylated and that this abnormality is restricted to the hinge region of IgA1 which contains 5 O-linked oligosaccharide side chains. The hinge region is primarily responsible for interactions of IgA1 with the asialoglycoprotein receptor (ASGP-R) on hepatocytes. The loss of hinge region galactose (Gal) results in increased plasma levels of IgA1, decreased binding to ASGP-R, but increased binding to kidneys and mesangial cells. Experimental approaches proposed in this application are designed to test the following hypothesis: An aberrant glycosylation pattern in a fraction of IgA1 proteins in IgAN patients leads to their altered elimination from the circulation and deposition in kidney mesangia. The following specific aims are proposed to obtain further evidence for this hypothesis: l) Perform comparative studies of carbohydrate moieties of serum and secretory IgA1 from IgAN patients and controls with respect to their reactivities with lectins and monoclonal antibodies specific for sialylated and non-sialylated forms N-acetylgalactosamine (Ga1NAc) and beta1-3 linked Gal; binding to receptors expressed on human hepatocytes, mesangial and monocytic cells; and carbohydrate compositions determined by a highly sensitive gas-liquid chromatography method. 2) Characterize the receptor(s) expressed on human mesangial cells specific for IgA1 molecules in various molecular forms having different glycosylation patterns. 3) Characterize IgA1 deposits in kidney biopsies from IgAN patients with respect to their reactivities with carbohydrate- specific lectins and monoclonal antibodies. 4) Provide evidence at the cellular level, for the secretion of IgA molecules with altered carbohydrate moieties by mitogen-stimulated and EBV-transformed peripheral blood lymphocytes from IgAN patients and healthy controls. 5) Correlate laboratory findings concerning the properties of aberrantly glycosylated IgA1 with the clinical course of the disease. Results of these studies should provide information concerning the behavior of structurally altered IgA1 proteins and provide a rational explanation for their deposition in kidney mesangium of IgAN patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049358-02
Application #
2150073
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1994-09-30
Project End
1999-08-31
Budget Start
1995-09-15
Budget End
1996-08-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Novak, Jan; Vu, Huong L; Novak, Lea et al. (2002) Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 62:465-75
Matousovic, K; Konecny, K; Myystecky, J et al. (2002) [IgA nephropathy. Significance of immunoglobulin A glycosylation in pathogenesis and clinical presentation] Cas Lek Cesk 141:729-34
Novak, J; Julian, B A; Tomana, M et al. (2001) Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol 21:310-27
Takahashi, T; Iwase, T; Tachibana, T et al. (2000) Cloning and expression of the chicken immunoglobulin joining (J)-chain cDNA. Immunogenetics 51:85-91
Novak, J; Tomana, M; Kilian, M et al. (2000) Heterogeneity of O-glycosylation in the hinge region of human IgA1. Mol Immunol 37:1047-56
Julian, B A (2000) Treatment of IgA nephropathy. Semin Nephrol 20:277-85
Julian, B A; Tomana, M; Novak, J et al. (1999) Progress in the pathogenesis of IgA nephropathy. Adv Nephrol Necker Hosp 29:53-72
Tomana, M; Novak, J; Julian, B A et al. (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104:73-81
Wyatt, R J; Julian, B A; Baehler, R W et al. (1998) Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994. Central Kentucky Region of the Southeastern United States IgA Nephropathy DATABANK Project. J Am Soc Nephrol 9:853-8
Tomana, M; Matousovic, K; Julian, B A et al. (1997) Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52:509-16

Showing the most recent 10 out of 11 publications